All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Marker chromosomes are structurally abnormal chromosomes that are rearranged to a level that prevents its allocation to one of the known 23 chromosomes hence indicating gross structural chromosomal damage. The prognostic impact of marker chromosomes in Acute Myeloid Leukemia (AML) is unclear hence the rationale of this study.
Tilmann Bochtler from the German Cancer Research Center, University of Heidelberg, Germany, and colleagues recently published results from their study ahead of print in Blood on 24th January 2017.
To assess the impact of marker chromosomes on the prognosis of AML patients and the mechanisms of marker chromosome formation, the authors retrospectively analyzed two prospective intensive chemotherapy trials, AML96 and AML2003 from the German Study Alliance Leukemia (SAL).
The presence of marker chromosomes suggest an activity of chromothripsis and can contribute to the poor prognosis in AML patients. Additionally, marker chromosomes do not reflect the poor prognosis of other adverse cytogenetic features, but can contribute to the poor prognostic impact by themselves in AML patients.
In summation, this is the first study to show that marker chromosomes can arise from chromothripsis, and it is frequently common in adverse-risk karyotypes and associated with a dismal prognosis in AML patients.
Metaphase karyotyping is an established diagnostic standard in acute myeloid leukemia (AML) for risk stratification. One of the cytogenetic findings in AML are structurally highly abnormal marker chromosomes. In this study we have assessed frequency, cytogenetic characteristics, prognostic impact and underlying biological origin of marker chromosomes. Given their inherent gross structural chromosomal damage, we speculated that they may arise from chromothripsis, a recently described phenomenon of chromosome fragmentation in a single catastrophic event. In 2 large consecutive prospective, randomized, multicenter, intensive chemotherapy trials (AML96, AML2003) from the Study Alliance Leukemia (SAL) marker chromosomes were detectable in 165/1026 (16.1%) of aberrant non-core-binding-factor (CBF) karyotype patients. Adverse-risk karyotypes displayed a higher frequency of marker chromosomes (26.5% in adverse-risk, 40.3% in complex aberrant and 41.2% in abnormality (17p) karyotypes, p<.0001 each). Marker chromosomes were associated with a poorer prognosis compared to other non-CBF aberrant karyotypes and led to lower remission rates (CR+CRi), inferior event-free survival as well as overall survival in both trials. In multivariate analysis, marker chromosomes independently predicted poor prognosis in the AML96 trial ≤60 years. As detected by array-CGH, about one third of marker chromosomes (18/49) had arisen from chromothripsis, whereas this phenomenon was virtually undetectable in a control group of marker chromosome-negative complex aberrant karyotypes (1/34). The chromothripsis-positive cases were characterized by a particularly high degree of karyotype complexity, TP53 mutations and dismal prognosis. In conclusion, marker chromosomes are indicative of chromothripsis and associated with poor prognosis per se and not merely by association with other adverse cytogenetic features.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox